The April 23 federal order moving marijuana to Schedule III has cannabis operators facing a new reality: prepare to be acquired, or prepare to acquire others.
Christopher B. Lynch, an attorney at Dickinson Wright PLLC, argues the rescheduling decision changes the competitive landscape in ways most cannabis businesses haven't fully grasped. "The practical question isn't whether this is something to celebrate, it's whether your business is positioned to be a consolidator, an attractive acquisition target or something different," Lynch wrote in an analysis published this week.
The rescheduling removes marijuana from Schedule I, where it sat alongside heroin and LSD, and places it in the same category as ketamine and anabolic steroids. That administrative change carries massive implications for how traditional industries can now approach the cannabis sector.
The Money Problem
Schedule III status doesn't legalize cannabis federally, but it does eliminate one of the industry's biggest financial burdens. Cannabis operators currently pay effective tax rates above 70% because IRS code 280E prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. A Schedule III designation ends that restriction.
The numbers tell the story: Multi-state operators have been burning through cash while posting paper losses despite strong revenue growth. Curaleaf reported $1.3 billion in revenue for 2023 but couldn't deduct rent, payroll or marketing costs. That changes under Schedule III.
But the tax relief comes with a trade-off. Pharmaceutical companies and agriculture conglomerates have stayed out of cannabis largely because of the Schedule I classification and its associated legal risks. Schedule III removes that barrier.
Who's Watching
Market watchers note that companies in adjacent industries have been positioning for this moment. Scotts Miracle-Gro spent years building hydroponics and cultivation equipment businesses. Altria, which makes Marlboro cigarettes, took a $1.8 billion stake in Canadian cannabis producer Cronos Group back in 2018, betting on eventual U.S. reform.
Lynch suggests cannabis operators need to assess their position now. Companies with strong brands, retail footprints or cultivation expertise could become acquisition targets. Smaller operators without scale or differentiation face a harder path.
The pharmaceutical angle presents particular challenges. Drug companies have the capital, regulatory experience and distribution networks to move quickly once the legal framework allows. They've also shown willingness to pay premium prices for assets in emerging therapeutic categories.
What Operators Should Do
Cannabis businesses need to clean up their operations if they want to attract buyers or compete with incoming players, according to Lynch. That means proper financial controls, documented compliance systems and clear intellectual property ownership.
Companies should also consider whether they want to remain independent or position for a sale. The window for advantageous deals may be narrow. Once larger players enter the market and prices compress, valuations will shift.
The rescheduling order still faces a comment period and potential legal challenges, but the direction is set. The Drug Enforcement Administration's decision follows a Health and Human Services recommendation from last year based on a review of marijuana's medical value and abuse potential.
For cannabis operators, the strategic question is no longer whether consolidation will happen. It's whether they'll be ready when it does.
This article is based on original reporting by www.marijuanamoment.net.
